Bosentan treatment of digital ulcers related to systemic sclerosis: Results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

Annals of the Rheumatic Diseases

Volumn 70, Issue 1, 2011, Pages 32-38

  Matucci Cerinic, Marco ^a   Denton, Christopher P ^b   Furst, Daniel E ^c   Mayes, Maureen D ^d   Hsu, Vivien M ^e   Carpentier, Patrick ^f   Wigley, Fredrick M ^g   Black, Carol M ^b   Fessler, Barri J ^h   Merke, Peter A ⁱ   Pope, Janet E ^j   Sweiss, Nadera J ^k   Doyle, Mittie K ^l,m,n   Hellmich, Bernhard ^o,p   Medsger Jr , Thomas A ^q   Morganti, Adele ^r   Kramer, Fabrice ^r   Korn, Joseph H ⁱ   Seibold, James R ^s  

^a UNIVERSITY OF FLORENCE   (Italy)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^f HÔPITAL MICHALLON   (France)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h University of Alabama at Birmingham   (United States)

ⁱ BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j Division of Rheumatology   (Canada)

^k UNIVERSITY OF CHICAGO   (United States)

^l TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m CENTOCOR INC   (United States)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

^o UNIVERSITY OF LÜBECK   (Germany)

^p Department of Medicine   (Germany)

^q UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^r ACTELION PHARMACEUTICALS LTD   (Switzerland)

^s UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PLACEBO; SILDENAFIL; VASODILATOR AGENT;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; DERMATITIS; DIARRHEA; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; ISCHEMIC DIGITAL ULCER; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PAIN ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; RECURRENT DISEASE; SIDE EFFECT; SKIN INFECTION; SKIN ULCER; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; ULCER HEALING; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADULT; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FINGERS; HAND DERMATOSES; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ENDOTHELIN; SCLERODERMA, SYSTEMIC; SKIN ULCER; SULFONAMIDES; TREATMENT OUTCOME; WOUND HEALING;

EID: 78650678451     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.130658     Document Type: Article

References (20)

1. Wigley FM. Vascular disease in scleroderma. Clin Rev Allergy Immunol 2009; 36 : 150-75.
2. Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66 : 754-63.
3. Mawdsley AH. Patient perception of UK scleroderma services - Results: of an anonymous questionnaire. Rheumatology (Oxford) 2006; 45 : 1573.
4. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81 : 139-53.
5. Steen V, Denton CP, Pope JE, et al. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology 2009; 48 ( Suppl 3 ): iii19 - 24.
6. Hachulla E, Clerson P, Launay D, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007; 34 : 2423-30.
7. Rademaker M, Cooke ED, Almond NE, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 1989; 298 : 561-4.
8. Wigley FM, Seibold JR, Wise RA, et al. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992; 19 : 1407-14.
9. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132 : 425-34.
10. Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol 2008; 35 : 1801 - 8.
11. Mayes MD. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003; 48 : 1190-9.
12. Hachulla E, Coghlan JG. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis 2004; 63 : 1009-14.
13. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346 : 896-903.
14. Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006; 65 : 1336-40.
15. Matucci-Cerinic M, Del Rosso A, Federico P, et al. Therapeutic challenges for systemic sclerosis: facts and future targets. Ann N Y Acad Sci 2007; 1110 : 448-54.
16. Korn JH, Mayes M, Matucci-Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50 : 3985-93.
17. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee SfSC. Arthritis Rheum 1980; 23 : 581-90.
18. Steen VD, Medsger TA, Jr, The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40 : 1984-91.
19. Merkel PA, Herlyn K, Martin RW, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46 : 2410-20.
20. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114 : 48-54.